Immunosyn

Immunosyn Corporation was a biopharmaceutical company primarily focused on the development and commercialization of SF-1019, a biologic drug candidate derived from goat serum. The company held exclusive worldwide marketing rights to the compound, which was purportedly designed to treat a variety of autoimmune and neurological conditions, including Multiple Sclerosis and diabetic neuropathy. Immunosyn became the subject of significant regulatory scrutiny and legal action by the SEC, which charged the company and its executives with defrauding investors by misrepresenting the drug's regulatory status and clinical trial progress. The company's operations effectively ceased following these legal challenges and the revocation of its securities registration. It is frequently cited as a prominent example of investment fraud within the penny stock biotechnology sector.